natgillin/translations-raw huggingface dataset:
In general, it can be assumed that these measures of anti-coagulant activity may reflect dabigatran levels and can provide guidance for the assessment of bleeding risk, i.e. exceeding the 90th percentile of dabigatran trough levels or a coagulation assay such as aPTT measured at trough (for aPTT thresholds see section 4.4, table 2) is considered to be associated with an increased risk of bleeding.
Općenito, može se smatrati da ove mjere antikoagulacijske aktivnosti mogu odražavati vrijednosti dabigatrana te mogu upućivati na ocjenu rizika od krvarenja, tj. kada prelaze 90. percentilu najnižih vrijednosti dabigatrana, ili se test koagulacije, kao što je aPTV, mjeren pri najnižim koncentracijama (za aPTV prag vidjeti tablicu 2 u dijelu 4.4), smatra povezanim s povećanim rizikom od krvarenja.
In general, minor bleeds required slightly lower, and more severe bleeds required up to three-fold higher median doses.
Općenito, za slabija krvarenja bile su potrebne nešto manje doze, a za obilnija krvarenja bile su potrebne trostruko veći medijani doze.
In general, paediatric patients require doses 1½ - 2 times higher than the adult doses to achieve similar blood levels.
Pedijatrijski bolesnici uglavnom zahtijevaju doze 1½ do 2 puta više od doza za odrasle da bi se postigle slične razine u krvi.
In general, rash manifests as a mild or moderate erythematous and acneiform rash, which may occur or worsen in areas exposed to sun.
Općenito, osip se manifestira u obliku blagog ili umjerenog eritematoznog i akneiformnog osipa koji se može pojaviti ili pogoršati na područjima koja su izložena suncu.
In general, rebound isolates either retained (if cross-resistant at baseline) or developed significant cross-resistance to indinavir, saquinavir and atazanavir.
Izolirani sojevi kod ponovnog ponovnog porasta broja virusa su, uglavnom, sadržavali (ako su bili križno rezistentni na početku) ili razvili značajnu križnu rezistenciju na indinavir, sakvinavir i atazanavir.
In general, rebound isolates either retained (if cross-resistant at baseline) or developed significant cross-resistance to indinavir, saquinavir and atazanavir.
Izolirani sojevi kod ponovnog porasta broja virusa su, uglavnom, sadržavali (ako su bili križno rezistentni na početku) ili razvili značajnu križnu rezistenciju na indinavir, sakvinavir i atazanavir.
In general, serotype- specific IgG GMCs were lower for preterm infants than term infants.
Općenito gledano, geometrijske sredine koncentracija protutijela IgG specifičnih za serotip bile su niže u prijevremeno rođene dojenčadi nego u dojenčadi koja su rođena u terminu.
In general, taking too much Axura should not result in any harm to you.
Općenito, uzimanje previše Axure ne bi Vam trebalo naškoditi.
In general, taking too much Ebixa should not result in any harm to you.
Općenito, uzimanje previše Ebixe ne bi Vam trebalo naškoditi.
In general, taking too much Marixino should not result in any harm to you.
Općenito, uzimanje previše lijeka Marixino ne bi Vam trebalo naškoditi.
In general, taking too much Memantine Merz should not result in any harm to you.
Općenito, uzimanje previše Memantine Merza ne bi Vam trebalo naškoditi.
In general, taking too much Memantine Mylan should not result in any harm to you.
Općenito, uzimanje previše Memantine Mylan ne bi Vam trebalo naškoditi.
In general, taking too much Memantine ratiopharm should not result in any harm to you.
Općenito, uzimanje previše Memantin ratiopharma ne bi Vam trebalo naškoditi.
In general, taking too much Nemdatine should not result in any harm to you.
Općenito, uzimanje previše lijeka Nemdatine ne bi Vam trebalo naškoditi.
In general, the ADRs in pJIA and sJIA patients were similar in type to those see in RA patients, see section 4.8.
Nuspojave kod bolesnika sa pJIA i sJIA općenito su bile slične onima zabilježenima kod bolesnika s RA, vidjeti dio 4.8.
In general, the adverse event profile in the limited children and adolescent population studied was similar to that observed in adults, although there is a paediatric-specific concern regarding growth inhibition, as decrease in height percentile (mean percentile decrease of growth velocity of 9 % percentile) and weight percentile (mean percentile decrease of 13 % percentile) were observed during treatment.
Profil nuspojava zabilježen u malobrojnoj ispitivanoj populaciji djece i adolescenata općenito je bio sličan onome u odraslih, uz problem specifičan za pedijatrijsku populaciju koji se odnosi na zastoj u rastu, jer su tijekom liječenja zabilježena smanjenja percentila tjelesne visine (srednja vrijednost smanjenja za 9 percentila) i percentila tjelesne težine (srednja vrijednost smanjenja za 13 percentila).
In general, the adverse event profile in the limited children and adolescent population studied was similar to that observed in adults, although there is a paediatric-specific concern regarding growth inhibition, as decrease in height percentile (mean percentile decrease of growth velocity of 9 percentile) and weight percentile (mean percentile decrease of 13 percentile) were observed during treatment.
Profil nuspojava zabilježen u malobrojnoj ispitivanoj populaciji djece i adolescenata općenito je bio sličan onome u odraslih, uz problem specifičan za pedijatrijsku populaciju koji se odnosi na zastoj u rastu, jer su tijekom liječenja zabilježena smanjenja percentila tjelesne visine (srednja vrijednost smanjenja za 9 percentila) i percentila tjelesne težine (srednja vrijednost smanjenja za 13 percentila).
In general, the adverse event profile reported with overdose was comparable to recommended single doses of Silgard.
Općenito, zabilježeni štetni događaji vezani uz predoziranje bili su slični onima vezanim uz preporučene doze cjepiva Silgard.
In general, the adverse events in paediatric patients with juvenile idiopathic arthritis were similar in frequency and type to those seen in adult patients (see below, Undesirable effects in adults).
Općenito, štetni događaji u pedijatrijskih bolesnika s juvenilnim idiopatskim artritisom po učestalosti i obliku bili su slični onima zabilježenim u odraslih bolesnika.
In general, the incidence of adverse reactions (especially “dizziness”) has been shown to be slightly higher in patients with a history of hypertension.
Općenito se pokazalo da je incidencija nuspojava (osobito “omaglica”) blago viša u bolesnika s hipertenzijom u anamanezi.
In general, the pharmacokinetics of emtricitabine in infants, children and adolescents (aged 4 months up to 18 years) are similar to those seen in adults.
Općenito je farmakokinetika emtricitabina u dojenčadi, djece i adolescenata (u dobi od 4 mjeseca do 18 godina) slična onoj u odraslih osoba.
In general, the side effects in children and adolescents are similar to those seen in adults.
Općenito gledano, nuspojave u djece i adolescenata, slične su onima opaženima u odraslih.
In general, treatment should be started at a low dose of 0.25 ml (62.5 microgram).
Općenito, liječenje treba započeti najmanjom dozom od 0,25 ml (62,5 mikrograma).
In general, treatment-emergent adverse events tended to decrease over time, perhaps accounted for by amelioration of the underlying disease process.
Općenito, štetni događaji koji su nastali tijekom liječenja težili su smanjivanju tijekom vremena, moguće zbog poboljšanja procesa osnovne bolesti.
In general, Xadago may be used with selective serotonin re-uptake inhibitors (SSRIs) at the lowest effective dose, with caution for serotoninergic symptoms.
Općenito, Xadago se može primjenjivati sa selektivnim inhibitorima ponovne pohrane serotonina (engl. selective serotonin re-uptake inhibitors, SSRI) u najnižoj učinkovitoj dozi uz oprez za serotoninergičke simptome.
In general, you will need to take special care to try and avoid effects of low blood pressure, such as fainting and dizziness:
Općenito, trebat ćete posebno paziti kako bi pokušali izbjeći učinke sniženog krvnog tlaka kao što su nesvjestica i omaglica:
In genotoxicity studies with other recombinant growth hormone preparations, there was no evidence of gene mutation in bacterial reverse mutation assays, chromosomal damage in human lymphocyte and mouse bone marrow cells, gene conversion in yeast or unscheduled DNA synthesis in human carcinoma cells.
Kod ispitivanja genotoksičnosti s drugim rekombinantnim hormonskim pripravcima nije bilo dokaza mutacije gena u ispitivanjima reverzne bakterijske mutacije, oštećenja kromosoma na humanim limfocitima i stanicama koštane srži miševa, konverzije gena kod kvasca ili neplanirane sinteze DNK na humanim stanicama karcinoma.
In genotype 3 infected patients experiencing virologic failure, development of NS5A RAVs (including enrichment of RAVs present at baseline) was typically not detected at the time of failure (n = 17).
U pacijenata zaraženih genotipom 3 u kojih je došlo do virološkog neuspjeha, razvoj NS5A RAV-ova (uključujući obogaćenje RAV-ova prisutno na početku) obično nije bio otkriven u vrijeme virološkog neuspjeha (n =17).
In genotype 4 replicons, single NS3 substitutions D168A/V reduced grazoprevir antiviral activity by 110- to 320-fold.
Kod replikona genotipa 4, pojedinačne supstitucije D168A/V u proteinu NS3 smanjile su antivirusnu aktivnost grazoprevira od 110 do 320 puta.
In genotype 4 replicons, single NS5A substitutions L30S, M31V, and Y93H reduced elbasvir antiviral activity by 3- to 23-fold.
Kod replikona genotipa 4, pojedinačne supstitucije L30S, M31V i Y93H u proteinu NS5A smanjile su antivirusnu aktivnost elbasvira od 3 do 23 puta.
In genotype 4a, resistance to paritaprevir or ombitasvir by variants in NS3 or NS5A, respectively, selected in cell culture were phenotypically characterised.
Kod genotipa 4a, fenotipski su okarakterizirane rezistencija na pariteprevir uzrokovana varijantama u NS3 te rezistencija na ombitasvir uzrokovana varijantama u NS5A, koje su izdvojene u staničnim kulturama.
In girls with Turner syndrome:
Kod djevojčica s Turnerovim sindromom:
In GIST patients (study B2222), 6.8 % of grade 3 or 4 ALT (alanine aminotransferase) elevations and 4.8 % of grade 3 or 4 AST (aspartate aminotransferase) elevations were observed.
U bolesnika s GIST-om (studija B2222), zapaženo je 6,8 % ALT (alanin-aminotransferaza) povišenja 3. ili 4. stupnja, kao i 4,8 % AST (aspartat- aminotransferaza) povišenja 3. ili 4. stupnja.
In GIST patients (study B2222), 6.8% of grade 3 or 4 ALT (alanine aminotransferase) elevations and 4.8% of grade 3 or 4 AST (aspartate aminotransferase) elevations were observed.
U bolesnika s GIST-om (studija B2222), zapaženo je 6,8% ALT (alanin-aminotransferaza) povišenja 3. ili 4. stupnja, kao i 4,8% AST (aspartat- aminotransferaza) povišenja 3. ili 4. stupnja.
In GIST patients (study B2222), 6.8% of grade 3 or 4 ALT (alanine aminotransferase) elevations and 4.8% of grade 3 or 4 AST (aspartate aminotransferase) elevations were observed.
U bolesnika s GIST-om (studija B2222), zapaženo je 6,8% povišenja ALT (alanin-aminotransferaza) 3. ili 4. stupnja, kao i 4,8% povišenja AST (aspartat- aminotransferaza) 3. ili 4. stupnja.
In GIST patients (study B2222), 6.8% of grade3 or 4 ALT (alanine aminotransferase) elevations and 4.8% of grade3 or 4 AST (aspartate aminotransferase) elevations were observed.
U bolesnika s GIST-om (studija B2222), zapaženo je 6,8% ALT (alanin-aminotransferaza) povišenja 3. ili 4. stupnja, kao i 4,8% AST (aspartat-aminotransferaza) povišenja 3. ili 4. stupnja.
In GIST patients ‘cardiac failure’, ‘cardiac failure congestive’ or ‘left ventricular failure’ were reported in 1.2% of patients treated with sunitinib and 1% of patients treated with placebo.
Među bolesnicima s GIST-om su "zatajenje srca", "kongestivno zatajenje srca" ili "'zatajenje lijeve klijetke" prijavljeni u 1,2% onih liječenih sunitinibom i u 1% onih koji su primali placebo.
In GIST the investigational medicinal product was discontinued for treatment-related adverse reactions in 4 % of patients.
U ispitivanju GIST-a, primjena ispitivanog lijeka je prekinuta u 4 % bolesnika zbog nuspojava povezanih s primjenom imatiniba.
In GIST the study medicinal product was discontinued for medicinal product-related adverse reactions in 4% of patients.
U ispitivanju GIST-a, primjena ispitivanog lijeka je prekinuta u 4% bolesnika zbog nuspojava povezanih s njegovom primjenom.
In GO-AFTER, the primary endpoint was the percentage of patients achieving an ACR 20 response at week 14.
Ankylosing Spondylitis Assessment Study Group, ASAS) u 14. tjednu.
In GO-BEFORE, the co-primary endpoints were the percentage of patients achieving ACR 50 response at week 24 and the change from baseline in the van der
U ispitivanju GO-BEFORE primarni su ishodi bili postotak bolesnika koji su postigli odgovor ACR 50 u
In GO-FORWARD and GO-AFTER, clinically meaningful and statistically significant responses in Disease Activity Scale (DAS)28 were observed at each prespecified time point, at week 14 and at week 24 (p ≤ 0.001).
U 14. i 24. tjednu primijećeni su statistički značajni odgovori i za BASDAI 50, 70 i 90 (p ≤ 0,017).
In gouty arthritis, both studies showed that Ilaris was more effective than triamcinolone acetonide at reducing pain intensity.
U slučaju uričnog artritisa, oba su ispitivanja pokazala da je lijek Ilaris djelotvorniji od triamcinolon acetonida u smanjivanju intenziteta boli.
In gouty arthritis, Ilaris was studied in two main studies involving 454 patients who were given either Ilaris or another anti-inflammatory medicine (triamcinolone acetonide) for 12 weeks.
U slučaju uričnog artritisa, Ilaris je ispitan u dva glavna ispitivanja koja su obuhvatila 454 bolesnika koji su primali Ilaris ili drugi protuupalni lijek (triamkinolon acetonid) tijekom 12 tjedana.
In gouty arthritis, treatment with Ilaris should be started and supervised by a specialist doctor experienced in diagnosing and treating gouty arthritis and in the use of biological medicines.
U slučaju uričnog artritisa, liječenje lijekom Ilaris smije započeti i nadgledati liječnik koji ima iskustva u dijagnosticiranju i liječenju uričnog artritisa te u primjeni bioloških lijekova.
In GPA and MPA, destroying the B-lymphocytes lowers the production of antibodies thought to play an important role in attacking the blood vessels and causing inflammation.
U bolesnika s bolestima GPA i MPA uništavanje B- limfocita smanjuje proizvodnju protutijela za koja se smatra da imaju važnu ulogu u napadu na krvne žile i uzrokovanje upale.
In HAE levels of a substance in your bloodstream called bradykinin are increased and this leads tosymptoms like swelling, pain, nausea, and diarrhoea.
Kod nasljednog angioedema (HAE) u Vašem su krvotoku povećane razine tvari koja se naziva bradikinin, što dovodi do simptoma kao što su oticanje, bol, mučnina i proljev.
In haemodialysed patients, a bolus injection may be given during the dialysis session through a suitable venous port in the dialysis line.
Kod bolesnika na hemodijalizi može se dati bolus injekcija tijekom postupka dijalize kroz prikladan venski put linije za dijalizu.
In haemodialysis patients and persons with an impaired immune system, adequate anti-HAV and anti-HBs antibody titres may not be obtained after the primary immunisation course and such patients may therefore require administration of additional doses of vaccine.
Može se dogoditi da bolesnici na hemodijalizi, te osobe s oslabljenim imunološkim sustavom nakon primarne imunizacije ne razviju adekvatan titar anti-HAV i anti-HBs protutijela, te će stoga u takvih bolesnika možda biti potrebno primijeniti dodatne doze cjepiva.
In haemodynamic studies, amlodipine has not been associated with a negative inotropic effect when administered in the therapeutic dose range to intact animals and humans, even when co-administered with beta blockers to humans.
U hemodinamskim ispitivanjima, amlodipin nije bio povezan s negativnim inotropnim učinkom kada se primjenjivao u rasponu terapijskih doza intaktnim životinjama i ljudima, čak i kada se primjenjivao istodobno s beta- blokatorima u ljudi.
In haemophilia, the dose is 90 micrograms per kilogram body weight, repeated every two to three hours until the bleeding is controlled.
U bolesnika s hemofilijom doza iznosi 90 mikrograma po kilogramu tjelesne težine koja se ponavlja svaka dva do tri sata do uspostave kontrole krvarenja.
In HBeAg negative patients without cirrhosis, treatment should be administered at least until HBs seroconversion or there is evidence of loss of efficacy.
Kod HBeAg negativnih pacijenata bez ciroze, liječenje se mora primjenjivati najmanje do pojave HBs serokonverzije ili do dokaza gubitaka djelotvornosti.
In HBeAg negative patients without cirrhosis, treatment should be administered at least until HBs seroconversion or there is evidence of loss of efficacy.
U HBeAg negativnih pacijenata bez ciroze, liječenje treba provoditi najmanje do pojave serokonverzije HBs ili dokazanog gubitka djelotvornosti.
In HBeAg positive adult patients, treatment should be administered at least until 12 months after achieving HBe seroconversion (HBeAg loss and HBV DNA loss with anti-HBe detection on two consecutive serum samples at least 3-6 months apart) or until HBs seroconversion or there is loss of efficacy (see section 4.4).
Kod HBeAg pozitivnih odraslih bolesnika, liječenje se mora primjenjivati barem do 12 mjeseci nakon postizanja HBe serokonverzije (nestanak HBeAg i nestanak HBV DNK s prisutnim anti- HBe na dva uzastopna mjerenja u uzorcima seruma u razmaku od najmanje 3-6 mjeseci) ili do HBs serokonverzije ili postoji gubitak djelotvornosti (vidjeti dio 4.4).
In HBeAg positive paediatric patients, treatment should be administered for at least 12 months after achieving undetectable HBV DNA and HBeAg seroconversion (HBeAg loss and anti-HBe detection on two consecutive serum samples at least 3-6 months apart) or until HBs seroconversion or there is loss of efficacy.
Kod HBeAg pozitivnih pedijatrijskih bolesnika liječenje treba primjenjivati najmanje 12 mjeseci nakon postizanja nemjerljivih razina HBV DNK i HBeAg serokonverzije (nestanak HBeAg i detekcija anti-HBe protutijela u dva uzastopna uzorka seruma u razmaku od najmanje 3 do 6 mjeseci) ili do HBs serokonverzije ili do gubitka djelotvornosti.
In HBeAg positive patients without cirrhosis, treatment should be administered for at least 6-12 months after HBe seroconversion (HBeAg loss and HBV DNA loss with anti-HBe detection) is confirmed or until HBs seroconversion or there is loss of efficacy (see section 4.4).
Kod HBeAg pozitivnih pacijenata bez ciroze, liječenje se mora primjenjivati najmanje 6 do 12 mjeseci nakon HBe serokonverzije (nestanak HBeAg i HBV DNK s detekcijom anti-HBe) ili sve do HBs serokonverzije ili do gubitka djelotvornosti (vidjeti dio 4.4).
In HBeAg positive patients without cirrhosis, treatment should be administered for at least 6-12 months after HBe seroconversion (HBeAg loss and HBV DNA loss with anti-HBe detection) is confirmed or until HBs seroconversion or there is loss of efficacy (see section 4.4).
U HBeAg pozitivnih pacijenata bez ciroze, liječenje treba provoditi najmanje 6 do 12 mjeseci nakon potvrde serokonverzije HBe (gubitak HbeAg-a i HBV DNK-a s detekcijom anti-HBe) ili do serokonverzije HBs ili gubitka djelotvornosti (vidjeti dio 4.4).
In HBeAg-negative patients with HBV DNA < 300 copies/ml at week 24, resistance was 0% (0/177) at 48 weeks and 5% (9/177) at week 104, whilst in patients with HBV DNA
U HBeAg-negativnih bolesnika s HBV DNK <300 kopija/ml u 24. tjednu, rezistencija je bila 0% (0/177) u 48. tjednu i 5% (9/177) u 104. tjednu, dok je u bolesnika s HBV DNK
In HBV infected patients, clinical and laboratory evidence of exacerbations of hepatitis have occurred after discontinuation of HBV therapy (see section 4.4).
U pacijenata inficiranih HBV-om javili su se klinički i laboratorijski dokazi egzacerbacija bolesti nakon prekida terapije hepatitisa B (vidjeti dio 4.4).
In HBV infected patients, clinical and laboratory evidence of hepatitis have occurred after discontinuation of treatment (see section 4.4).
U bolesnika zaraženih HBV-om se nakon prekida liječenja mogao klinički i laboratorijski dokazati hepatitis (vidjeti dio 4.4).
In HCV clinical trials, a higher incidence of gastrointestinal bleeding, including serious and fatal cases, was reported following discontinuation of peginterferon, ribavirin, and eltrombopag.
U kliničkim ispitivanjima HCV-a, nakon prestanka uzimanja peginterferona, ribavirina i eltrombopaga ustanovljena je povećana incidencija krvarenja iz probavnog sustava, uključujući ozbiljne i slučajeve opasne po život.
In HCV genotype 1a infected patients without cirrhosis, simeprevir efficacy in combination with sofosbuvir at the recommended 12-week treatment duration was not impacted by the presence of the NS3 Q80K polymorphism (see section 5.1).
U bolesnika s infekcijom HCV genotipa 1a bez ciroze na djelotvornost simeprevira u kombinaciji sa sofosbuvirom nije utjecala prisutnost NS3 Q80K polimorfizma kod preporučenog trajanja liječenja od 12 tjedana (vidjeti dio 5.1).
In HCV negative patients with moderate hepatic impairment, reduced
U bolesnika negativnih na HCV s umjerenim oštećenjem funkcije jetre primijećena je smanjena izloženost telapreviru.
In HCV/HIV co-infected patients receiving cART, the following other side effects have occurred with the combination of ribavirin and peginterferon alfa-2b (not listed above in adults side effects):
U bolesnika istodobno zaraženih HCV-om/HIV-om koji primaju kombiniranu terapiju antiretrovirusnim lijekovima pojavile su se sljedeće druge nuspojave u kombinaciji ribavirina i peginterferona alfa-2b (nisu navedene u dijelu nuspojava u odraslih):
In HCV/HIV co-infected patients receiving cART, the following other side effects have occurred with the combination of ribavirin hard capsules and peginterferon alfa-2b (not listed above in adults side effects):
U bolesnika s istodobnom infekcijom HCV-om i HIV-om koji primaju kombiniranu antiretrovirusnu terapiju (cART) i kombiniranu terapiju ribavirin tvrdim kapsulama i peginterferonom alfa-2b, javile su se i sljedeće nuspojave (koje nisu prethodno navedene među nuspojavama u odraslih bolesnika):
In HCV/HIV co-infected patients receiving HAART, the following other side effects have occurred with the combination of ribavirin and peginterferon alfa-2b (not listed above in adults side effects):
U bolesnika s istodobnom infekcijom HCV-om i HIV-om koji primaju vrlo djelotvornu antiretrovirusnu terapiju (HAART) i kombiniranu terapiju ribavirinom i peginterferonom alfa-2b, javile su se i sljedeće nuspojave (koje nisu prethodno navedene među nuspojavama u odraslih bolesnika):
In healthy adult subjects (males and females), following administration of FOSAVANCE after an overnight fast and two hours before a meal, the mean area under the serum-concentration-time curve (AUC0-120 hrs) for vitamin D3 (unadjusted for endogenous vitamin D3 levels) was 296.4 nghr/ml.
Prosječna površina ispod krivulje koncentracija u serumu : vrijeme (AUC0-120 hrs) za vitamin D3 u zdravih je odraslih ispitanika (oba spola) nakon primjene FOSAVANCE tableta natašte i dva sata prije obroka (bez prilagodbe za endogene razine vitamina D3) iznosila 296,4 nghr/ml.
In healthy adult subjects (males and females), following administration of VANTAVO 70 mg/5600 IU after an overnight fast and two hours before a meal, the mean area under the serum-concentration-time curve (AUC0-80 hrs) for vitamin D3 (unadjusted for endogenous vitamin D3 levels) was 490.2 nghr/ml.
Prosječna površina ispod krivulje koncentracija u serumu : vrijeme (AUC0-80 hrs) za vitamin D3 u zdravih je odraslih ispitanika (oba spola) nakon primjene VANTAVO 70 mg/5600 IU tableta natašte i dva sata prije obroka (bez prilagodbe za endogene razine vitamina D3) iznosila 490,2 nghr/ml.
In healthy adult subjects (males and females), following administration of VANTAVO after an overnight fast and two hours before a meal, the mean area under the serum-concentration-time curve (AUC0-120 hrs) for vitamin D3 (unadjusted for endogenous vitamin D3 levels) was 296.4 nghr/ml.
Prosječna površina ispod krivulje koncentracija u serumu : vrijeme (AUC0-120 hrs) za vitamin D3 u zdravih je odraslih ispitanika (oba spola) nakon primjene VANTAVO tableta natašte i dva sata prije obroka (bez prilagodbe za endogene razine vitamina D3) iznosila 296,4 nghr/ml.